Health
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations – GlobeNewswire
– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal…
Second Product Candidate Expected to Enter Clinic in First Half of 2021
Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options
PHILADELPHIA, Jan. 28, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS)…
-
Noosa News19 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News20 hours agoMotorcyclist dies in crash with truck
-
Noosa News21 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
Noosa News19 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush